[go: up one dir, main page]

MX2016013875A - Active ingredient (i) containing composition and method for preparing same. - Google Patents

Active ingredient (i) containing composition and method for preparing same.

Info

Publication number
MX2016013875A
MX2016013875A MX2016013875A MX2016013875A MX2016013875A MX 2016013875 A MX2016013875 A MX 2016013875A MX 2016013875 A MX2016013875 A MX 2016013875A MX 2016013875 A MX2016013875 A MX 2016013875A MX 2016013875 A MX2016013875 A MX 2016013875A
Authority
MX
Mexico
Prior art keywords
active ingredient
present
composition
containing composition
preparing same
Prior art date
Application number
MX2016013875A
Other languages
Spanish (es)
Inventor
Keun-Ho Ryu
Park Jun-Sung
Shin Dongchul
chul SHIN Ho
HWANG Sang-wook
Kim Gwan-Young
Taek KIM Hun-
Original Assignee
Sk Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Chemicals Co Ltd filed Critical Sk Chemicals Co Ltd
Publication of MX2016013875A publication Critical patent/MX2016013875A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Polyethers (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

The present invention relates to a composition, prepared by a melt extrusion method, comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3- oxazolidin-5-yl}-methyl]-2-thiophene carboxamide as an active ingredient. The composition according to the present invention has a wide variety of advantages, such as securing an elution rate and bioavailability of an active ingredient, improving an absorption deviation according to whether a patient has a meal or not, securing stability during the preparation process, etc. Also, the present invention provides a method for preparing such a composition.
MX2016013875A 2014-04-22 2015-04-22 Active ingredient (i) containing composition and method for preparing same. MX2016013875A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140048064A KR101499867B1 (en) 2014-04-22 2014-04-22 Composition comprising active agent (I) and manufacturing method thereof
PCT/KR2015/004021 WO2015163689A1 (en) 2014-04-22 2015-04-22 Active ingredient (i) containing composition and method for preparing same

Publications (1)

Publication Number Publication Date
MX2016013875A true MX2016013875A (en) 2017-05-12

Family

ID=53026662

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013875A MX2016013875A (en) 2014-04-22 2015-04-22 Active ingredient (i) containing composition and method for preparing same.

Country Status (10)

Country Link
US (1) US20170049782A1 (en)
EP (1) EP3135299A4 (en)
JP (2) JP2017513878A (en)
KR (1) KR101499867B1 (en)
CN (1) CN106456788A (en)
AU (1) AU2015250470B2 (en)
BR (1) BR112016024825A2 (en)
CA (1) CA2946701C (en)
MX (1) MX2016013875A (en)
WO (1) WO2015163689A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105726499B (en) * 2016-02-01 2020-09-08 深圳信立泰药业股份有限公司 Rivaroxaban pharmaceutical composition and preparation method thereof
KR102282186B1 (en) 2018-09-21 2021-07-27 동아에스티 주식회사 A solubilized composition comprising rivaroxaban

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4327063A1 (en) * 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenone particles with modified physicochemical properties
DE19962924A1 (en) * 1999-12-24 2001-07-05 Bayer Ag Substituted oxazolidinones and their use
DE102004062475A1 (en) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Solid, orally administrable, modified release pharmaceutical dosage forms
DE102005047561A1 (en) * 2005-10-04 2007-04-05 Bayer Healthcare Ag Drug delivery system, useful to treat and/or prevent e.g. thromboembolic disease, comprises 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxo-4-morpholinyl)-phenyl)-1,3-oxazolidine-5-yl)-methyl)-2-thiophene carboxamide with fast release active substance
EP2262477A1 (en) * 2008-03-04 2010-12-22 F. Hoffmann-La Roche AG Process for preparing concentrated aqueous micellar solutions
EP2485715A1 (en) * 2009-10-06 2012-08-15 Ratiopharm GmbH Pharmaceutical compositions comprising rivaroxaban
AR082862A1 (en) * 2010-09-02 2013-01-16 Gruenenthal Gmbh ALTERATION RESISTANT DOSAGE FORM INCLUDING AN ANIONIC POLYMER
MX2013010306A (en) * 2011-03-08 2013-12-09 Zalicus Pharmaceuticals Ltd Solid dispersion formulations and methods of use thereof.
WO2014016842A1 (en) * 2012-07-23 2014-01-30 Symed Labs Limited Amorphous coprecipitates of rivaroxaban

Also Published As

Publication number Publication date
AU2015250470B2 (en) 2017-06-29
CA2946701C (en) 2019-02-19
BR112016024825A2 (en) 2017-08-15
US20170049782A1 (en) 2017-02-23
CN106456788A (en) 2017-02-22
EP3135299A4 (en) 2017-12-27
EP3135299A1 (en) 2017-03-01
CA2946701A1 (en) 2015-10-29
AU2015250470A1 (en) 2016-12-01
WO2015163689A1 (en) 2015-10-29
JP2017513878A (en) 2017-06-01
KR101499867B1 (en) 2015-03-06
JP2018123140A (en) 2018-08-09

Similar Documents

Publication Publication Date Title
PH12018502516A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12017502315A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
SA517390586B1 (en) New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12017502266B1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
JO3675B1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12018502515B1 (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
GEP20207117B (en) Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
MY185491A (en) Macrocylic pyrimidine derivatives
CY1122506T1 (en) CRYSTAL FORM OF THE COMPOUND (S)-3-{4-[5-(2-CYCLOPENTYL-6-METHOXY- PYRIDIN-4- YL)-[1,2,4]OXADIAZOL-3- YL]-2- ETHYL- 6-METHYL- PHENOXY}-PROPANE-1,2-DIOL
EA201691741A1 (en) PHARMACEUTICAL COMPOSITION
MD4780B1 (en) P-substituted asymmetric ureas and medical uses thereof
PH12016501903A1 (en) Novel fused imidazobenzothiazole compounds
EA201792234A1 (en) NEW PYRIDINIA CONNECTIONS
MX2017008074A (en) IMIDAZOPYRIDAZINE DERIVATIVES AS PI3Kß INHIBITORS.
MX2016013875A (en) Active ingredient (i) containing composition and method for preparing same.
WO2012080184A3 (en) Liquid pharmaceutical compositions which can be administered orally and contain 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophene carboxamide
PH12016500980B1 (en) Amide derivatives for gpr119 agonist
MX2017008076A (en) Heterocyclyl linked imidazopyridazine derivatives as pi3kbeta inhibitors.
WO2014141067A3 (en) Process for the preparation of oxazolidinone derivatives
IN2013MU03508A (en)
IL250168A0 (en) Novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition containing same
IN2014MU00666A (en)